| 4017 | Humans (MeSH) |
| 3962 | Animals (MeSH) |
| 2102 | Male (MeSH) |
| 1607 | Female (MeSH) |
| 1409 | Mice (MeSH) |
| 1036 | Rats (MeSH) |
| 1012 | Models, Biological (MeSH) |
| 627 | Adult (MeSH) |
| 589 | Middle Aged (MeSH) |
| 511 | Disease Models, Animal (MeSH) |
| 500 | Cell Line, Tumor (MeSH) |
| 485 | Antineoplastic Agents (pharmacology) |
| 484 | Dose-Response Relationship, Drug (MeSH) |
| 481 | Cells, Cultured (MeSH) |
| 446 | Time Factors (MeSH) |
| 424 | Apoptosis (drug effects) |
| 394 | Mice, Inbred C57BL (MeSH) |
| 393 | Rats, Sprague-Dawley (MeSH) |
| 374 | Aged (MeSH) |
| 350 | Cell Line (MeSH) |
| 339 | Treatment Outcome (MeSH) |
| 331 | Rats, Wistar (MeSH) |
| 325 | Signal Transduction (drug effects) |
| 315 | Cell Proliferation (drug effects) |
| 315 | Anti-Bacterial Agents (pharmacology) |
| 287 | Anti-Inflammatory Agents (pharmacology) |
| 281 | Amino Acid Sequence (MeSH) |
| 280 | Tumor Necrosis Factor-alpha (antagonists & inhibitors) |
| 275 | Signal Transduction (MeSH) |
| 275 | Cell Survival (drug effects) |
| 271 | Hypoglycemic Agents (pharmacology) |
| 270 | Mice, Inbred BALB C (MeSH) |
| 266 | Molecular Sequence Data (MeSH) |
| 256 | Biological Availability (MeSH) |
| 250 | Cytokines (metabolism) |
| 244 | Antineoplastic Agents (therapeutic use) |
| 234 | Hypoglycemic Agents (therapeutic use) |
| 217 | Case-Control Studies (MeSH) |
| 211 | Hypoglycemic Agents (administration & dosage) |
| 195 | Microbial Sensitivity Tests (MeSH) |
| 191 | Blood Glucose (metabolism) |
| 183 | Biological Transport (MeSH) |
| 179 | Tumor Necrosis Factor-alpha (metabolism) |
| 179 | In Vitro Techniques (MeSH) |
| 177 | Anti-Inflammatory Agents (therapeutic use) |
| 173 | Neuroprotective Agents (pharmacology) |
| 170 | Immunosuppressive Agents (therapeutic use) |
| 169 | Peptides (chemistry) |
| 169 | NF-kappa B (metabolism) |
| 169 | Diabetes Mellitus, Type 2 (drug therapy) |
| 169 | Biological Products (therapeutic use) |
| 168 | Insulin (administration & dosage) |
| 167 | RNA, Messenger (metabolism) |
| 167 | Administration, Oral (MeSH) |
| 166 | Phosphorylation (MeSH) |
| 166 | Adolescent (MeSH) |
| 164 | Oxidative Stress (drug effects) |
| 163 | Blotting, Western (MeSH) |
| 162 | Plant Extracts (pharmacology) |
| 160 | Kinetics (MeSH) |
| 160 | Biological Transport (drug effects) |
| 160 | Arthritis, Rheumatoid (drug therapy) |
| 155 | Structure-Activity Relationship (MeSH) |
| 154 | Antirheumatic Agents (therapeutic use) |
| 152 | Gene Expression Regulation (drug effects) |
| 151 | Neoplasms (drug therapy) |
| 150 | Antibodies, Monoclonal (therapeutic use) |
| 148 | Peptides (pharmacology) |
| 147 | Drug Therapy, Combination (MeSH) |
| 146 | Antineoplastic Agents (chemistry) |
| 144 | Young Adult (MeSH) |
| 143 | Enzyme Inhibitors (pharmacology) |
| 140 | Tumor Cells, Cultured (MeSH) |
| 140 | Insulin (metabolism) |
| 136 | Insulin (pharmacology) |
| 135 | Liver (drug effects) |
| 134 | Antioxidants (pharmacology) |
| 133 | Biomarkers (blood) |
| 132 | Liver (metabolism) |
| 130 | Mice, Nude (MeSH) |
| 130 | Insulin (blood) |
| 126 | Reactive Oxygen Species (metabolism) |
| 125 | Glutathione (metabolism) |
| 121 | Risk Factors (MeSH) |
| 121 | Apoptosis (MeSH) |
| 120 | Transfection (MeSH) |
| 120 | Mutation (MeSH) |
| 120 | Mice, Knockout (MeSH) |
| 117 | Antifungal Agents (pharmacology) |
| 116 | Glucose (metabolism) |
| 115 | Molecular Structure (MeSH) |
| 115 | Gene Expression Regulation (MeSH) |
| 114 | Plant Diseases (microbiology) |
| 112 | Immunosuppressive Agents (pharmacology) |
| 110 | Insulin (therapeutic use) |
| 109 | Drug Design (MeSH) |
| 108 | Child (MeSH) |
| 106 | Protein Binding (MeSH) |
| 106 | Drug Delivery Systems (MeSH) |
| 106 | Diabetes Mellitus, Type 1 (drug therapy) |
| 106 | Antiviral Agents (pharmacology) |
| 105 | Neurons (drug effects) |
| 104 | Xenograft Model Antitumor Assays (MeSH) |
| 104 | Blood Glucose (drug effects) |
| 103 | Biological Assay (MeSH) |
| 102 | Disease Progression (MeSH) |
| 102 | Anti-Inflammatory Agents, Non-Steroidal (pharmacology) |
| 101 | Protective Agents (pharmacology) |
| 100 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 100 | Enzyme-Linked Immunosorbent Assay (MeSH) |
| 99 | Cell Movement (drug effects) |
| 98 | Nitric Oxide (metabolism) |
| 98 | Inflammation (drug therapy) |
| 98 | Immunohistochemistry (MeSH) |
| 98 | Drug Administration Schedule (MeSH) |
| 98 | Computer Simulation (MeSH) |
| 98 | Caspase 3 (metabolism) |
| 97 | Rabbits (MeSH) |
| 97 | Mice, Transgenic (MeSH) |
| 97 | Clinical Trials as Topic (MeSH) |
| 95 | Neoplasms (metabolism) |
| 95 | Calcium (metabolism) |
| 95 | Base Sequence (MeSH) |
| 95 | Aged, 80 and over (MeSH) |
| 94 | Signal Transduction (physiology) |
| 94 | Neurons (metabolism) |
| 94 | Brain (metabolism) |
| 94 | Algorithms (MeSH) |
| 93 | Inflammation (prevention & control) |
| 93 | Gene Expression (MeSH) |
| 93 | Drug Synergism (MeSH) |
| 92 | Inflammation (metabolism) |
| 92 | Cattle (MeSH) |
| 91 | Prospective Studies (MeSH) |
| 91 | Pregnancy (MeSH) |
| 91 | Antineoplastic Agents (administration & dosage) |
| 90 | Blood Glucose (analysis) |
| 89 | RNA, Messenger (genetics) |
| 89 | Interleukin-6 (metabolism) |
| 88 | Retrospective Studies (MeSH) |
| 88 | Neuroprotective Agents (therapeutic use) |
| 88 | Anti-Infective Agents (pharmacology) |
| 87 | Macrophages (drug effects) |
| 87 | Inflammation Mediators (metabolism) |
| 87 | Cell Proliferation (MeSH) |
| 87 | Anti-Bacterial Agents (chemistry) |
| 86 | Models, Molecular (MeSH) |
| 86 | Macrophages (metabolism) |
| 86 | Bacterial Proteins (genetics) |
| 85 | Severity of Illness Index (MeSH) |
| 85 | Peptide Fragments (pharmacology) |
| 84 | Swine (MeSH) |
| 84 | Hydrogen-Ion Concentration (MeSH) |
| 83 | Recombinant Proteins (pharmacology) |
| 83 | Cell Division (drug effects) |
| 82 | Pest Control, Biological (MeSH) |
| 82 | Chromatography, High Pressure Liquid (MeSH) |
| 81 | Vasodilator Agents (pharmacology) |
| 81 | Insulin Resistance (MeSH) |
| 81 | Hypoglycemic Agents (pharmacokinetics) |
| 81 | Antiviral Agents (therapeutic use) |
| 80 | Random Allocation (MeSH) |
| 80 | Phytotherapy (MeSH) |
| 80 | Graft Rejection (prevention & control) |
| 80 | Biological Products (pharmacology) |
| 80 | Anti-Bacterial Agents (therapeutic use) |
| 79 | Proto-Oncogene Proteins c-bcl-2 (metabolism) |
| 79 | Phosphorylation (drug effects) |
| 79 | Peptides (metabolism) |
| 79 | Gene Expression Profiling (MeSH) |
| 79 | Brain (drug effects) |
| 79 | Antineoplastic Agents, Phytogenic (pharmacology) |
| 78 | Reproducibility of Results (MeSH) |
| 78 | Immunosuppressive Agents (administration & dosage) |
| 77 | Drug Screening Assays, Antitumor (MeSH) |
| 77 | Biological Control Agents (MeSH) |
| 76 | Diabetes Mellitus, Experimental (drug therapy) |
| 76 | Cytokines (blood) |
| 76 | Cyclosporine (therapeutic use) |
| 76 | Bacterial Proteins (metabolism) |
| 75 | Phenotype (MeSH) |
| 75 | Oligopeptides (pharmacology) |
| 75 | Infliximab (MeSH) |
| 75 | Drug Evaluation, Preclinical (MeSH) |
| 75 | Area Under Curve (MeSH) |
| 75 | Anti-Inflammatory Agents, Non-Steroidal (therapeutic use) |
| 74 | Breast Neoplasms (drug therapy) |
| 74 | Analysis of Variance (MeSH) |
| 73 | Proto-Oncogene Proteins c-akt (metabolism) |
| 73 | Ligands (MeSH) |
| 72 | Neoplasms (pathology) |
| 72 | Lipopolysaccharides (pharmacology) |
| 72 | HeLa Cells (MeSH) |
| 72 | Diabetes Mellitus, Type 1 (blood) |
| 71 | Particle Size (MeSH) |
| 71 | Gene Expression Regulation, Neoplastic (drug effects) |
| 71 | Etanercept (MeSH) |
| 71 | Cloning, Molecular (MeSH) |
| 71 | Cell Membrane (metabolism) |
| 70 | Vascular Endothelial Growth Factor A (metabolism) |
| 70 | Up-Regulation (MeSH) |
| 70 | Tumor Necrosis Factor-alpha (immunology) |
| 70 | Neovascularization, Pathologic (prevention & control) |
| 70 | Liver (pathology) |
| 70 | Immunosuppressive Agents (pharmacokinetics) |
| 70 | Flow Cytometry (MeSH) |
| 70 | Cell Cycle (drug effects) |
| 70 | Blood Pressure (drug effects) |
| 69 | Peptides, Cyclic (pharmacology) |
| 69 | Follow-Up Studies (MeSH) |
| 68 | Recombinant Proteins (MeSH) |
| 68 | Randomized Controlled Trials as Topic (MeSH) |
| 67 | Prognosis (MeSH) |
| 67 | Gene Expression (drug effects) |
| 67 | Breast Neoplasms (pathology) |
| 66 | Endothelium, Vascular (drug effects) |
| 66 | Drug Carriers (chemistry) |
| 66 | Diabetes Mellitus, Type 2 (metabolism) |
| 66 | Cyclosporine (pharmacokinetics) |
| 65 | Tissue Distribution (MeSH) |
| 65 | Mitochondria (metabolism) |
| 65 | Cell Survival (MeSH) |
| 65 | Antineoplastic Agents (chemical synthesis) |
| 64 | Hypoglycemic Agents (adverse effects) |
| 64 | Cytokines (genetics) |
| 64 | Biological Products (adverse effects) |
| 63 | Plant Diseases (prevention & control) |
| 63 | Lung (drug effects) |
| 62 | Cytokines (immunology) |
| 62 | Antibodies, Monoclonal, Humanized (therapeutic use) |
| 62 | Antibodies, Monoclonal, Humanized (MeSH) |
| 61 | Sequence Analysis, DNA (MeSH) |
| 61 | Rats, Inbred Strains (MeSH) |
| 61 | Oxidative Stress (MeSH) |
| 61 | Gene Expression Regulation, Neoplastic (MeSH) |
| 61 | Down-Regulation (MeSH) |
| 61 | Breast Neoplasms (metabolism) |
| 61 | Binding Sites (MeSH) |
| 61 | Antirheumatic Agents (adverse effects) |
| 60 | Mitogen-Activated Protein Kinases (metabolism) |
| 60 | Hypoglycemic Agents (chemistry) |
| 60 | Enzyme Activation (drug effects) |
| 60 | Cell Differentiation (drug effects) |
| 60 | Antioxidants (metabolism) |
| 59 | T-Lymphocytes (immunology) |
| 59 | Protein Kinase Inhibitors (pharmacology) |
| 59 | Phylogeny (MeSH) |
| 59 | Nanoparticles (chemistry) |
| 59 | Down-Regulation (drug effects) |
| 59 | Cyclosporine (pharmacology) |
| 59 | Body Weight (drug effects) |
| 59 | Antibodies, Monoclonal (adverse effects) |
| 58 | Psoriasis (drug therapy) |
| 58 | Predictive Value of Tests (MeSH) |
| 58 | Mitochondria (drug effects) |
| 58 | Cyclosporine (administration & dosage) |
| 58 | Antioxidants (therapeutic use) |
| 57 | Tumor Necrosis Factor-alpha (pharmacology) |
| 57 | Oligopeptides (chemistry) |
| 57 | Insulin Secretion (MeSH) |
| 56 | Myocardium (metabolism) |
| 56 | Lung (pathology) |
| 56 | Caspases (metabolism) |
| 56 | Bacteria (drug effects) |
| 56 | Antifungal Agents (metabolism) |
| 55 | Up-Regulation (drug effects) |
| 55 | Plant Extracts (chemistry) |
| 55 | Neoplasms (prevention & control) |
| 55 | Insulin (pharmacokinetics) |
| 55 | Immunoglobulin G (therapeutic use) |
| 55 | Enzyme Activation (MeSH) |
| 55 | Diabetes Mellitus, Type 2 (blood) |
| 55 | Cytokines (biosynthesis) |
| 55 | Apoptosis (physiology) |
| 54 | Receptors, Tumor Necrosis Factor (therapeutic use) |
| 54 | Plant Extracts (therapeutic use) |
| 54 | Mice, Inbred ICR (MeSH) |
| 54 | Immunosuppressive Agents (adverse effects) |
| 54 | Dogs (MeSH) |
| 54 | Cricetinae (MeSH) |
| 54 | Antimicrobial Cationic Peptides (pharmacology) |
| 53 | Tumor Necrosis Factor-alpha (genetics) |
| 53 | Peptide Hydrolases (metabolism) |
| 53 | Oxidation-Reduction (MeSH) |
| 53 | Neoplasm Transplantation (MeSH) |
| 53 | Hippocampus (drug effects) |
| 53 | Cell Membrane (drug effects) |
| 53 | Biofilms (drug effects) |
| 53 | Antineoplastic Agents (adverse effects) |
| 53 | Antihypertensive Agents (pharmacology) |
| 53 | Anti-Inflammatory Agents (administration & dosage) |
| 52 | Lipopeptides (pharmacology) |
| 52 | Hypertension (drug therapy) |
| 52 | HEK293 Cells (MeSH) |
| 52 | Cell Death (drug effects) |
| 52 | Cardiotonic Agents (pharmacology) |
| 52 | Biomarkers (metabolism) |
| 52 | Amyloid beta-Peptides (metabolism) |
| 52 | Alzheimer Disease (metabolism) |
| 52 | AMP-Activated Protein Kinases (metabolism) |
| 51 | Survival Analysis (MeSH) |
| 51 | Superoxide Dismutase (metabolism) |
| 51 | Recombinant Proteins (metabolism) |
| 51 | Lipid Peroxidation (drug effects) |
| 51 | Fibroblasts (drug effects) |
| 51 | Drug Stability (MeSH) |
| 51 | Child, Preschool (MeSH) |
| 51 | Anti-Bacterial Agents (administration & dosage) |
| 50 | Protein-Serine-Threonine Kinases (metabolism) |
| 50 | Protein Conformation (MeSH) |
| 50 | Peptides, Cyclic (chemistry) |
| 50 | NF-kappa B (antagonists & inhibitors) |
| 50 | Escherichia coli (genetics) |
| 50 | Diabetes Mellitus, Experimental (metabolism) |
| 50 | Chronic Disease (MeSH) |
| 50 | Anticarcinogenic Agents (pharmacology) |
| 50 | Anti-Inflammatory Agents (chemistry) |
| 49 | T-Lymphocytes (drug effects) |
| 49 | Real-Time Polymerase Chain Reaction (MeSH) |
| 49 | Molecular Weight (MeSH) |
| 49 | Macrophages (immunology) |
| 49 | Interleukin-1beta (metabolism) |
| 49 | Inflammation (pathology) |
| 49 | Endothelium, Vascular (metabolism) |
| 49 | Drug Interactions (MeSH) |
| 49 | Drug Delivery Systems (methods) |
| 49 | Angiogenesis Inhibitors (pharmacology) |
| 48 | Molecular Targeted Therapy (MeSH) |
| 48 | Methotrexate (therapeutic use) |
| 48 | Mass Spectrometry (MeSH) |
| 48 | Kidney (drug effects) |
| 48 | Insulin Infusion Systems (MeSH) |
| 48 | Injections, Subcutaneous (MeSH) |
| 48 | Double-Blind Method (MeSH) |
| 48 | Animals, Newborn (MeSH) |
| 47 | Tumor Necrosis Factor-alpha (blood) |
| 47 | Temperature (MeSH) |
| 47 | Staphylococcus aureus (drug effects) |
| 47 | Solubility (MeSH) |
| 47 | Polyethylene Glycols (chemistry) |
| 47 | Hippocampus (metabolism) |
| 47 | Flavonoids (pharmacology) |
| 47 | Antibodies, Monoclonal (pharmacology) |
| 47 | Antibiosis (MeSH) |
| 46 | Transcription Factors (metabolism) |
| 46 | Pest Control, Biological (methods) |
| 46 | Peptide Fragments (metabolism) |
| 46 | Drug Carriers (MeSH) |
| 46 | Adalimumab (MeSH) |
| 45 | STAT3 Transcription Factor (metabolism) |
| 45 | Neurotransmitter Agents (physiology) |
| 45 | Intestinal Mucosa (metabolism) |
| 45 | Inflammation (immunology) |
| 44 | p38 Mitogen-Activated Protein Kinases (metabolism) |
| 44 | Vasodilation (drug effects) |
| 44 | Vasoconstrictor Agents (pharmacology) |
| 44 | Polymerase Chain Reaction (MeSH) |
| 44 | Obesity (metabolism) |
| 44 | Hep G2 Cells (MeSH) |
| 44 | Genotype (MeSH) |
| 44 | Escherichia coli (drug effects) |
| 44 | Antineoplastic Agents (pharmacokinetics) |
| 44 | Antifungal Agents (chemistry) |
| 43 | bcl-2-Associated X Protein (metabolism) |
| 43 | Dietary Supplements (MeSH) |
| 42 | Species Specificity (MeSH) |
| 42 | Protein Structure, Tertiary (MeSH) |
| 42 | Protective Agents (therapeutic use) |
| 42 | Neurons (pathology) |
| 42 | Lung (metabolism) |
| 42 | Inflammation (MeSH) |
| 42 | Immunologic Factors (therapeutic use) |
| 42 | Hypoglycemia (prevention & control) |
| 42 | Hyperglycemia (prevention & control) |
| 42 | Cyclic AMP (metabolism) |
| 42 | Chemistry, Pharmaceutical (MeSH) |
| 42 | Cardiovascular Diseases (prevention & control) |
| 42 | Antibodies, Monoclonal (administration & dosage) |
| 42 | Adipocytes (metabolism) |
| 41 | Tumor Necrosis Factor-alpha (biosynthesis) |
| 41 | Surface Properties (MeSH) |
| 41 | Recombinant Fusion Proteins (genetics) |
| 41 | RNA Interference (MeSH) |
| 41 | RAW 264.7 Cells (MeSH) |
| 41 | Myocytes, Cardiac (drug effects) |
| 41 | Molecular Docking Simulation (MeSH) |
| 41 | Matrix Metalloproteinase 9 (metabolism) |
| 41 | Lipopeptides (metabolism) |
| 41 | Interleukin-6 (blood) |
| 41 | Half-Life (MeSH) |
| 41 | Glucose Tolerance Test (MeSH) |
| 41 | Fungi (drug effects) |
| 41 | Drug Combinations (MeSH) |
| 41 | Cyclooxygenase 2 (metabolism) |
| 41 | Combined Modality Therapy (MeSH) |
| 41 | Cohort Studies (MeSH) |
| 41 | Biological Transport (physiology) |
| 41 | Arthritis, Rheumatoid (immunology) |
| 41 | Anti-Bacterial Agents (metabolism) |
| 40 | Recombinant Proteins (therapeutic use) |
| 40 | Recombinant Proteins (genetics) |
| 40 | RNA, Messenger (biosynthesis) |
| 40 | Phosphatidylinositol 3-Kinases (metabolism) |
| 40 | Peptides (administration & dosage) |
| 40 | Peptide Fragments (chemistry) |
| 40 | Inhibitory Concentration 50 (MeSH) |
| 40 | Infant, Newborn (MeSH) |
| 40 | Heart (drug effects) |
| 40 | Fibroblasts (metabolism) |
| 40 | Endothelial Cells (metabolism) |
| 40 | DNA-Binding Proteins (metabolism) |
| 40 | Cytokines (antagonists & inhibitors) |
| 40 | Cell Differentiation (MeSH) |
| 40 | Caco-2 Cells (MeSH) |
| 40 | Behavior, Animal (drug effects) |
| 40 | Acetylcholine (pharmacology) |
| 39 | Sequence Homology, Amino Acid (MeSH) |
| 39 | Risk Assessment (MeSH) |
| 39 | Peptides (therapeutic use) |
| 39 | Neurotransmitter Agents (metabolism) |
| 39 | MAP Kinase Signaling System (drug effects) |
| 39 | Insulin (adverse effects) |
| 39 | Injections, Intravenous (MeSH) |
| 39 | Epithelial Cells (drug effects) |
| 39 | Biological Control Agents (pharmacology) |
| 39 | Anti-Infective Agents (chemistry) |
| 39 | Anti-Bacterial Agents (pharmacokinetics) |
| 39 | Alzheimer Disease (drug therapy) |
| 38 | Vancomycin (pharmacology) |
| 38 | Reperfusion Injury (prevention & control) |
| 38 | Peptides, Cyclic (metabolism) |
| 38 | Neutrophils (drug effects) |
| 38 | Lung Neoplasms (pathology) |
| 38 | Injections, Intraperitoneal (MeSH) |
| 38 | Homeostasis (MeSH) |
| 38 | Extracellular Signal-Regulated MAP Kinases (metabolism) |
| 38 | Drug Resistance, Neoplasm (MeSH) |
| 38 | Diabetes Mellitus (drug therapy) |
| 38 | Cross-Sectional Studies (MeSH) |
| 38 | Cell Nucleus (metabolism) |
| 38 | Biological Products (administration & dosage) |
| 38 | Antineoplastic Agents (metabolism) |
| 38 | Adenosine Triphosphate (metabolism) |
| 37 | Virus Replication (drug effects) |
| 37 | Sequence Alignment (MeSH) |
| 37 | Sensitivity and Specificity (MeSH) |
| 37 | Protein Kinase C (metabolism) |
| 37 | Prostatic Neoplasms (pathology) |
| 37 | Nitric Oxide Synthase Type II (metabolism) |
| 37 | Neoplasm Invasiveness (prevention & control) |
| 37 | Myocardium (pathology) |
| 37 | MCF-7 Cells (MeSH) |
| 37 | Lipopolysaccharides (MeSH) |
| 37 | Interferon-alpha (therapeutic use) |
| 37 | Inflammation (chemically induced) |
| 37 | Incidence (MeSH) |
| 37 | Endothelial Cells (drug effects) |
| 37 | Electrophoresis, Polyacrylamide Gel (MeSH) |
| 37 | Drug Liberation (MeSH) |
| 37 | Diabetes Mellitus, Type 2 (complications) |
| 37 | Cell Division (MeSH) |
| 37 | Bacillus (metabolism) |
| 37 | Alzheimer Disease (prevention & control) |
| 36 | Tumor Suppressor Protein p53 (metabolism) |
| 36 | Transcription, Genetic (MeSH) |
| 36 | Promoter Regions, Genetic (MeSH) |
| 36 | Obesity (drug therapy) |
| 36 | Neoplasms (therapy) |
| 36 | Myocytes, Cardiac (metabolism) |
| 36 | Microscopy, Fluorescence (MeSH) |
| 36 | Larva (drug effects) |
| 36 | Insulin-Secreting Cells (metabolism) |
| 36 | Inflammatory Bowel Diseases (drug therapy) |
| 36 | Diabetes Mellitus, Type 1 (metabolism) |
| 36 | Carrier Proteins (metabolism) |
| 36 | Biological Transport, Active (drug effects) |
| 36 | Antimicrobial Cationic Peptides (chemistry) |
| 36 | Antihypertensive Agents (therapeutic use) |
| 36 | Angiogenesis Inhibitors (therapeutic use) |
| 35 | Transforming Growth Factor beta (metabolism) |
| 35 | Transcription Factors (genetics) |
| 35 | Proteins (metabolism) |
| 35 | Neoplasm Invasiveness (MeSH) |
| 35 | Muscle, Smooth, Vascular (drug effects) |
| 35 | Matrix Metalloproteinase 2 (metabolism) |
| 35 | Lung Neoplasms (drug therapy) |
| 35 | Kidney (metabolism) |
| 35 | Immunologic Factors (pharmacology) |
| 35 | Imidazoles (pharmacology) |
| 35 | Hypertension (physiopathology) |
| 35 | Drug Compounding (MeSH) |
| 35 | DNA Damage (MeSH) |
| 35 | Brain (pathology) |
| 35 | Apoptosis Regulatory Proteins (metabolism) |
| 35 | Anti-Bacterial Agents (biosynthesis) |
| 35 | Adipose Tissue (metabolism) |
| 34 | Soil Microbiology (MeSH) |
| 34 | Pancreas, Artificial (MeSH) |
| 34 | Neutrophils (metabolism) |
| 34 | Neoplasms (genetics) |
